Ripretinib

Ripretinib (Qinlock, Deciphera Pharmaceuticals (Netherlands) B.V.) has 1 EU-approved indication in 1 tumour type.
Approved indications of Ripretinib
Biomarker requirementRegimenSettingConditions
Gastrointestinal stromal tumour1
None
Monotherapy
3L+
advanced
After three or more prior kinase inhibitors, including imatinib
Full text of section 4.1 (therapeutic indications)

QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Label history

10 changes to the Qinlock label since 2022, none of them to the indications. Newest first, in the words of EMA's record of each procedure.

Changes